Omnicell Inc (OMCL) is a publicly traded Healthcare sector company. As of October 29, 2026, OMCL trades at $35.16 with a market cap of $1.68B and a P/E ratio of 41.51. OMCL moved -2.20% today. Year to date, OMCL is -20.36%; over the trailing twelve months it is +20.07%. Its 52-week range spans $22.66 to $55.00. Analyst consensus is strong buy with an average price target of $56.00. Rallies surfaces OMCL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Omnicell raises 2026 EBITDA and EPS guidance as Q3 revenue slips 1%: Omnicell raised its 2026 non-GAAP EBITDA guidance to $187 million-$193 million and EPS outlook to $2.48-$2.56, while narrowing its revenue guidance to $1.225 billion-$1.231 billion. Q3 revenue fell 1% year over year to $308 million; GAAP net income was $11 million and adjusted EBITDA was $45 million.
| Metric | Value |
|---|---|
| Price | $35.16 |
| Market Cap | $1.68B |
| P/E Ratio | 41.51 |
| EPS | $0.85 |
| Dividend Yield | 0.00% |
| 52-Week High | $55.00 |
| 52-Week Low | $22.66 |
| Volume | 1.27K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.25B |
| Net Income | $39.08M |
| Gross Margin | 44.77% |
7 analysts cover OMCL: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $56.00.